Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
EDQM
0
USP
0
JP
0
Others
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
US Medicaid
NA
Annual Reports
NA
Regulatory FDF Prices
NA
0
API
0
FDF
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz
1. Cefaloglycin
2. Cephaloglycin Dihydrate
3. Cephaloglycine
4. Dihydrate, Cephaloglycin
1. Cefaloglycin
2. Cephaloglycine
3. D-cephaloglycine
4. Cephaoglycin Acid
5. Cephaloglycin Anhydrous
6. 3577-01-3
7. Cefaloglycine
8. Cefaloglicina
9. Cefaloglycinum
10. D-(-)-cephaloglycin
11. 7-(d-alpha-aminophenyl-acetamido)cephalosporanic Acid
12. 7-(2-d-alpha-aminophenylacetamido)cephalosporanic Acid
13. Cefaloglycin (jan)
14. Cefaloglycin [inn]
15. Chebi:34613
16. Kefglycin
17. (6r,7r)-3-(acetyloxymethyl)-7-[[(2r)-2-amino-2-phenylacetyl]amino]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic Acid
18. Ceg
19. Cephaloglycin Dihydrate
20. Hd2d469w6u
21. Kefocin
22. 7-(d-2-amino-2-phenylacetamido)-3-acetoxymethyl-delta(sup3)-cephem-4-carboxylic Acid
23. Cefaloglycin [jan]
24. Cefaloglycin Dihydrate
25. Cefaloglycine [inn-french]
26. Cefaloglycinum [inn-latin]
27. Cefaloglicina [inn-spanish]
28. Lilly 39435
29. 5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic Acid,3-[(acetyloxy)methyl]-7-[[(2r)-aminophenylacetyl]amino]-8-oxo-,(6r,7r)-
30. Hsdb 3214
31. Einecs 222-696-7
32. Cephaloglycin Anhdyous
33. 7-(2-amino-2-phenylacetamido)-3-(hydroxymethyl)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic Acid Acetate (ester)
34. Cephaloglycin [mi]
35. Epitope Id:174844
36. Schembl2947
37. 7-(d-2-amino-2-phenylacetamido)-3-acetoxymethyl-delta(sup 3)-cephem-4-carboxylic Acid
38. Cephaloglycin [hsdb]
39. Unii-hd2d469w6u
40. 3-((acetyloxy)methyl)-7-((aminophenylacetyl)amino)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic Acid
41. 5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic Acid, 3-((acetyloxy)methyl)-7-((aminophenylacetyl)amino)-8-oxo-, (6r-(6alpha,7beta(r*)))-
42. 7-(2-amino-2-phenylacetamido)-3-(hydroxymethyl)-8-oxo-5-thia-1-azabicyclo(4.2.0)octane-2-carboxylic Acid, Acetate Inner Salt
43. Cefaloglycin [who-dd]
44. Chembl1200971
45. Dtxsid4022781
46. Gtpl12193
47. Zinc3830503
48. Db00689
49. 3-acetoxymethyl-7beta-[(2r)-2-amino-2-phenylacetamido]-3,4-didehydrocepham-4-carboxylic Acid
50. Ncgc00521078-02
51. (6r,7r)-3-(acetoxymethyl)-7-{[(2r)-2-amino-2-phenylacetyl]amino}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic Acid
52. (6r,7r)-3-[(acetyloxy)methyl]-7-{[(2r)-2-amino-2-phenylacetyl]amino}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic Acid
53. 5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic Acid, 7-(2-amino-2-phenylacetamido)-3-(hydroxymethyl)-8-oxo-, Acetate (ester), D-
54. Hy-16137
55. Cs-0006156
56. D01949
57. Q5057214
58. (6r,7r)-3-[(acetyloxy)methyl]-7-[(2r)-2-amino-2-phenylacetamido]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic Acid
59. (6r,7r)-7-((r)-2-amino-2-phenylacetamido)-3-(hydroxymethyl)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic Acid Acetate (ester)
60. 5-thia-1-azabicyclo(4.2.0)oct-2-ene-carboxylic Acid, 3-((acetyloxy)methyl)-7-((aminophenylacetyl)amino)-8-oxo-, (6r-(6.alpha.,7.beta.(r*)))
| Molecular Weight | 405.4 g/mol |
|---|---|
| Molecular Formula | C18H19N3O6S |
| XLogP3 | -3 |
| Hydrogen Bond Donor Count | 3 |
| Hydrogen Bond Acceptor Count | 8 |
| Rotatable Bond Count | 7 |
| Exact Mass | 405.09945651 g/mol |
| Monoisotopic Mass | 405.09945651 g/mol |
| Topological Polar Surface Area | 164 Ų |
| Heavy Atom Count | 28 |
| Formal Charge | 0 |
| Complexity | 718 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 3 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Cephalosporins
National Library of Medicine's Medical Subject Headings online file (MeSH, 1999)
...BECAUSE CEPHALOGLYCIN IS CONCENTRATED IN URINE, IT MAY BE EFFECTIVE IN TREATMENT OF URINARY TRACT INFECTIONS... /DIHYDRATE/
Osol, A. and J.E. Hoover, et al. (eds.). Remington's Pharmaceutical Sciences. 15th ed. Easton, Pennsylvania: Mack Publishing Co., 1975., p. 1120
MOST OF CEPHALOGLYCIN...IS EXCRETED IN URINE AS DEACETYLCEPHALOGLYCIN, AN ANTIMICROBIALLY ACTIVE METABOLITE. URINARY CONCN OF METABOLITE AVG 350 UG/ML OVER 8-HR PERIOD FOLLOWING ADMIN OF 500 MG OF CEPHALOGLYCIN; THIS IS SUFFICIENT TO INHIBIT MOST STRAINS OF E COLI, MIRABILIS, & KLEBSIELLA-ENTEROBACTER (AEROBACTER) GROUP.
Goodman, L.S., and A. Gilman. (eds.) The Pharmacological Basis of Therapeutics. 5th ed. New York: Macmillan Publishing Co., Inc., 1975., p. 1162
ITS IN VITRO SPECTRUM IS SIMILAR TO THAT OF OTHER CEPHALOSPORINS...& INCL MANY PATHOGENS THAT INFECT URINARY TRACT (EG, ESCHERICHIA COLI, CERTAIN SPECIES OF KLEBSIELLA, STAPHYLOCOCCUS AUREUS). /DIHYDRATE/
American Medical Association, AMA Department of Drugs, AMA Drug Evaluations. 3rd ed. Littleton, Massachusetts: PSG Publishing Co., Inc., 1977., p. 722
For more Therapeutic Uses (Complete) data for CEPHALOGLYCIN (7 total), please visit the HSDB record page.
...CEPHALOGLYCIN IS NOT DRUG OF CHOICE FOR TREATING URINARY TRACT INFECTIONS... IS NOT EVEN A CEPHALOSPORIN OF 1ST CHOICE FOR SEVERE URINARY TRACT INFECTIONS. AVAILABILITY OF...CEPHALOSPORINS...EXCRETED BY KIDNEY...ACHIEVING HIGHER BACTERICIDAL CONCN IN URINE THAN CEPHALOGLYCIN...RENDERED CEPHALOGLYCIN OBSOLETE. /DIHYDRATE/
American Medical Association, AMA Department of Drugs, AMA Drug Evaluations. 3rd ed. Littleton, Massachusetts: PSG Publishing Co., Inc., 1977., p. 722
CEPHALOGLYCIN IS INEFFECTIVE AGAINST PSEUDOMONAS, & MOST SPECIES OF ENTEROCOCCI, ENTEROBACTER, & INDOLE-POSITIVE PROTENS. BECAUSE OF LIMITED ABSORPTION, SERUM LEVELS OF DRUG ADEQUATE TO TREAT SYSTEMIC INFECTIONS CANNOT BE ATTAINED CLINICALLY. /DIHYDRATE/
American Medical Association, AMA Department of Drugs, AMA Drug Evaluations. 3rd ed. Littleton, Massachusetts: PSG Publishing Co., Inc., 1977., p. 722
SUPRAINFECTIONS, USUALLY DUE TO GRAM-NEGATIVE BACTERIA, MAY OCCUR WHEN THESE ANTIBIOTICS ARE EMPLOYED. /CEPHALOSPORINS/
Goodman, L.S., and A. Gilman. (eds.) The Pharmacological Basis of Therapeutics. 5th ed. New York: Macmillan Publishing Co., Inc., 1975., p. 1163
Hypersensitivity reactions to the cephalosporins are the most common side effects...the reactions appear to be identical to those caused by the penicillins. /Cephalosporins/
Hardman, J.G., L.E. Limbird, P.B. Molinoff, R.W. Ruddon, A.G. Goodman (eds.). Goodman and Gilman's The Pharmacological Basis of Therapeutics. 9th ed. New York, NY: McGraw-Hill, 1996., p. 1095
For more Drug Warnings (Complete) data for CEPHALOGLYCIN (12 total), please visit the HSDB record page.
For treatment of severe infections caused by susceptible bacteria.
Cephaloglycin is an antibiotic related to cephalosporin but no longer in common use. It is an orally absorbed derivative of cephalosporin C.
Anti-Bacterial Agents
Substances that inhibit the growth or reproduction of BACTERIA. (See all compounds classified as Anti-Bacterial Agents.)
Absorption
Well absorbed following oral administration.
MOST OF CEPHALOGLYCIN THAT IS ABSORBED IS EXCRETED IN URINE AS DEACETYLCEPHALOGLYCIN, AN ANTIMICROBIALLY ACTIVE METABOLITE. URINARY CONCN OF METABOLITE AVG 350 UG/ML OVER 8-HR PERIOD FOLLOWING ADMIN OF 500 MG OF CEPHALOGLYCIN...
Goodman, L.S., and A. Gilman. (eds.) The Pharmacological Basis of Therapeutics. 5th ed. New York: Macmillan Publishing Co., Inc., 1975., p. 1162
CEPHALOGLYCIN IS NOT DESTROYED IN GASTRIC ACID, BUT IT GRADUALLY DECOMP IN NEUTRAL & ALKALINE SECRETIONS OF INTESTINES. ONLY 1/4 TO 1/3 IS ABSORBED. /DIHYDRATE/
Osol, A. and J.E. Hoover, et al. (eds.). Remington's Pharmaceutical Sciences. 15th ed. Easton, Pennsylvania: Mack Publishing Co., 1975., p. 1120
...CEPHALOSPORINS ARE UNPREDICTABLE IN MANNER IN WHICH THEY CROSS BLOOD-BRAIN BARRIER & THEY PENETRATE POORLY INTO CEREBROSPINAL FLUID... /CEPHALOSPORINS/
American Medical Association, AMA Department of Drugs, AMA Drug Evaluations. 3rd ed. Littleton, Massachusetts: PSG Publishing Co., Inc., 1977., p. 713
MOST OF CEPHALOGLYCIN THAT IS ABSORBED IS EXCRETED...AS DEACETYLCEPHALOGLYCIN, AN ANTIMICROBIALLY ACTIVE METABOLITE.
Goodman, L.S., and A. Gilman. (eds.) The Pharmacological Basis of Therapeutics. 5th ed. New York: Macmillan Publishing Co., Inc., 1975., p. 1162
THIS ANTIBIOTIC IS PARTIALLY ABSORBED FROM GI TRACT... PLASMA CONCN REACH PEAK OF ONLY 2-6 UG/ML @ ABOUT 2 HR FOLLOWING SINGLE DOSE OF 0.5 G; DRUG IS NO LONGER DETECTABLE IN PLASMA 8 HR AFTER THIS DOSE. HALF-LIFE...IS ABOUT 4 HR.
Goodman, L.S., and A. Gilman. (eds.) The Pharmacological Basis of Therapeutics. 5th ed. New York: Macmillan Publishing Co., Inc., 1975., p. 1162
PLASMA LEVELS AFTER ORAL ADMIN VARY WIDELY AMONG PT. PEAK LEVEL OF AT LEAST 0.6 UG/ML IS USUALLY ACHIEVED WITH ORAL DOSE OF 500 MG, & IT MAY REACH 6 UG/ML IN FAIR PROP OF CASES. FOOD IN STOMACH INTERFERES WITH ABSORPTION. HALF-LIFE IN PLASMA...ABOUT 3-5 HR, BUT WHEN...SEVERE RENAL IMPAIRMENT...MAY BE 9-20 HR. /DIHYDRATE/
Osol, A. and J.E. Hoover, et al. (eds.). Remington's Pharmaceutical Sciences. 15th ed. Easton, Pennsylvania: Mack Publishing Co., 1975., p. 1120
The bactericidal activity of cephaloglycin results from the inhibition of cell wall synthesis via affinity for penicillin-binding proteins (PBPs).
CEPHALOTHIN & ITS CONGENERS INHIBIT BACTERIAL CELL-WALL SYNTHESIS IN MANNER SIMILAR TO THAT OF PENICILLIN. /CEPHALOTHIN & ITS CONGENERS/
Goodman, L.S., and A. Gilman. (eds.) The Pharmacological Basis of Therapeutics. 5th ed. New York: Macmillan Publishing Co., Inc., 1975., p. 1160
/PENICILLINS & CEPHALOSPORINS/...HAVE SIMILAR MECHANISM OF ANTIBACTERIAL ACTION; BOTH INTERFERE WITH TERMINAL STEP IN BACTERIAL CELL WALL SYNTH BY INACTIVATING TRANSPEPTIDASE, THEREFORE PREVENTING CROSS-LINKAGE OF PEPTIDOGLYCAN CHAINS. /PENICILLINS & CEPHALOSPORINS/
American Medical Association, AMA Department of Drugs, AMA Drug Evaluations. 3rd ed. Littleton, Massachusetts: PSG Publishing Co., Inc., 1977., p. 712
ABOUT THIS PAGE
40
PharmaCompass offers a list of Cephaloglycin API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Cephaloglycin manufacturer or Cephaloglycin supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Cephaloglycin manufacturer or Cephaloglycin supplier.
PharmaCompass also assists you with knowing the Cephaloglycin API Price utilized in the formulation of products. Cephaloglycin API Price is not always fixed or binding as the Cephaloglycin Price is obtained through a variety of data sources. The Cephaloglycin Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Cephaloglycin manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Cephaloglycin, including repackagers and relabelers. The FDA regulates Cephaloglycin manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Cephaloglycin API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Cephaloglycin supplier is an individual or a company that provides Cephaloglycin active pharmaceutical ingredient (API) or Cephaloglycin finished formulations upon request. The Cephaloglycin suppliers may include Cephaloglycin API manufacturers, exporters, distributors and traders.
Cephaloglycin Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Cephaloglycin GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Cephaloglycin GMP manufacturer or Cephaloglycin GMP API supplier for your needs.
A Cephaloglycin CoA (Certificate of Analysis) is a formal document that attests to Cephaloglycin's compliance with Cephaloglycin specifications and serves as a tool for batch-level quality control.
Cephaloglycin CoA mostly includes findings from lab analyses of a specific batch. For each Cephaloglycin CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Cephaloglycin may be tested according to a variety of international standards, such as European Pharmacopoeia (Cephaloglycin EP), Cephaloglycin JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Cephaloglycin USP).
